Cerus Corporation (NASDAQ: CERS) announced today that 32 studies on the company’s INTERCEPT Blood System have been accepted for presentation at the International Congress of the International Society of Blood Transfusion to be held in Macao SAR, China, June 7-12, 2008. The studies reported include information on clinical experience from implementation of the INTERCEPT Blood System in routine practice, support of patients with severe congenital bleeding disorders undergoing major surgery, the inactivation of protozoa and Avian influenza virus, patient outcomes from hemovigilence surveillance programs for platelets and plasma, as well as results from clinical studies of the modified red blood cell system.
“As our pathogen inactivation technology enters into routine use, data continue to emerge supporting the effectiveness and safety of the INTERCEPT Blood System in improving the clinical outcomes for patients who require blood transfusion therapy. The extensive spectrum of presentations at ISBT focuses on the impact of pathogen inactivation using INTERCEPT on patient outcomes, logistics and economics,” said Laurence Corash, M.D., senior vice president and chief medical officer at Cerus Corporation. “This evidence provides support for adoption of the INTERCEPT Blood System.”
Key Presentations of Interest Include:
Photochemical Inactivation with Amotosalen and UVA Light of Protozoan Parasites in Platelet and Plasma Components Using INTERCEPT Blood System
- The study evaluates the efficacy of the INTERCEPT platelet and plasma systems to inactivate parasites in blood for transfusion, potentially eliminating the need for donor travel deferrals and testing, a cost and time benefit to blood banks, while increasing the available donor pool.
Inactivation of Influenza Virus Type A H5N1 in Platelets and Plasma by Treatment with the INTERCEPT Blood System
- The study evaluates the efficacy of the INTERCEPT platelet and plasma systems to inactivate avian flu virus, a pathogen not currently being tested for in donor blood. In the event of a flu pandemic, pathogen inactivation offers the potential to maintain an adequate and safe blood supply.
Intensive and Successful Transfusion of Pathogen Inactivated INTERCEPT Platelet Concentrates for Major Gynecological and Obstetrical Surgery in Glanzmann Thrombasthenia Type 1 with Gypsy Mutation
- The study demonstrates the ability of INTERCEPT-treated platelets to support two patients in surgical procedures with severe congenital platelet disorders. This is the first demonstration that patients with a congenital bleeding disorder were safely managed through surgical procedures with platelets treated with pathogen inactivation.
Clinical Experience with Conventional Versus INTERCEPT Platelet Concentrates Transfused to All Patients During Two One-Year Periods: Reduction of Adverse Events with Equivalent Use of Blood Products
- The study provides data on routine use of the INTERCEPT platelet system, comparing patient responses to INTERCEPT-treated platelets in additive solution versus conventional platelets suspended in 100% plasma.
Implementation of Pathogen Inactivated Therapeutic Apheresis Plasma Following Photochemical Treatment with INTERCEPT by EFS-Alsace, a French Regional Blood Center
- The study evaluates the implementation in routine use of INTERCEPT-treated plasma for transfusion in place of quarantined plasma. The study demonstrated that the INTERCEPT plasma system could be used to replace quarantined plasma to meet the needs of a regional blood center.
A Randomized, Single-Blind, Controlled, 2-Period Crossover Study of Recovery and Lifespan of Radiolabeled Autologous 35-day-old Red Blood Cells Prepared with a Modified S-303 Treatment Process (mS-303 RBCs) for Pathogen Inactivation
- The study evaluated the recovery and life span of autologous red blood cells prepared with the company’s modified process and stored for 35 days in healthy volunteers.
The INTERCEPT Blood System
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens, such as viruses, bacteria and parasites, as well as harmful white blood cells, that may be present in donated blood intended for transfusion. The system inactivates pathogens in platelets and plasma using the same proprietary illumination device, process and active compound. The INTERCEPT Blood System is designed to be easily incorporated into the typical operations of blood banks and to provide protection against a broad spectrum of known and emerging pathogens. The INTERCEPT Blood System has received CE mark approvals for both the platelet and plasma systems.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements including references to the commercial acceptance of the INTERCEPT Blood System. Words such as "believe," "should," "expect" and similar words or expressions or the negative of these words or expressions are intended to identify forward-looking statements. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
William J. Dawson, Vice President, Finance &
CFO Account Director
Porter Novelli Life Sciences
Jason I. Spark